# US 2019/0314474 A1 · Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0314474 A1 - Document ID: US20190314474A1 - Status: Published application - Kind: A1 - Application number: 16/415,552 - Filed: 2019-05-17 - Published: 2019-10-17 - Earliest claimed: 2016-02-19 - Assignees: Immatics Biotechnologies GmbH - Applicants: Immatics Biotechnologies GmbH - Inventors: Oliver SCHOOR; Andrea MAHR; Toni WEINSCHENK; Anita WIEBE; Jens FRITSCHE; Harpreet SINGH - Web page: https://patentgrep.com/patent/US20190314474A1 ## CPC - C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} - A61K 39/0011: {Cancer antigens} - A61K 39/001193: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR} - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/42: Cancer antigens - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - C07K 14/7051: {T-cell receptor (TcR)-CD3 complex} - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - C07K 16/30: from tumour cells - C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]} - C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells} - A61K 2039/605: {MHC molecules or ligands thereof} - C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies - C12N 2310/16: Aptamers - C12N 2501/50: Cell markers; Cell surface determinants - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/156: Polymorphic or mutational markers - C12Q 2600/158: Expression markers - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N 2800/7028: Cancer - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. ## Claims ### Claim 1 A method of eliciting an immune response in a HLA-A*02+ patient who has cancer, comprising administering to the patient a population of activated antigen-specific CD8+ cytotoxic T cells that kill cancer cells that present at their surface a peptide consisting of the amino acid sequence selected from SEQ ID NO: 120, SEQ ID NO: 203, SEQ ID NO: 2 to SEQ ID NO: 112, SEQ ID NO: 114 to SEQ ID NO: 119, SEQ ID NO: 121 to SEQ ID NO: 145, SEQ ID NO: 147 to SEQ ID NO: 202, SEQ ID NO: 204 to SEQ ID NO: 273, and SEQ ID NO: 275 to SEQ ID NO: 328, in a complex with an MHC class I molecule, wherein the activated antigen-specific CD8+ cytotoxic cells are produced by a method comprising contacting in vitro CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of the amino acid sequence selected from SEQ ID NO: 120, SEQ ID NO: 203, SEQ ID NO: 2 to SEQ ID NO: 112, SEQ ID NO: 114 to SEQ ID NO: 119, SEQ ID NO: 121 to SEQ ID NO: 145, SEQ ID NO: 147 to SEQ ID NO: 202, SEQ ID NO: 204 to SEQ ID NO: 273, and SEQ ID NO: 275 to SEQ ID NO: 328 in a complex with an MHC class I molecule, wherein said cancer is selected from the group consisting of non-Hodgkin lymphomas, acute myelogenous leukemia, chronic lymphocytic leukemia, uterine cancer, lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, and bile duct cancer. ### Claim 2 (depends on 1) The method of claim 1, wherein the T cells are autologous to the patient. ### Claim 3 (depends on 1) The method of claim 1, wherein the T cells are obtained from a healthy donor. ### Claim 4 (depends on 1) The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. ### Claim 5 (depends on 1) The method of claim 1, wherein the activated T cells are expanded in vitro. ### Claim 6 (depends on 1) The method of claim 1, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide. ### Claim 7 (depends on 6) The method of claim 6, wherein the antigen presenting cell is a dendritic cell or a macrophage. ### Claim 8 (depends on 5) The method of claim 5, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12. ### Claim 9 (depends on 1) The method of claim 1, wherein the population of activated T cells are administered in the form of a composition. ### Claim 10 (depends on 9) The method of claim 9, wherein the composition comprises an adjuvant. ### Claim 11 (depends on 10) The method of claim 10, wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 12 (depends on 10) The method of claim 10, wherein the adjuvant comprises IL-21. ### Claim 13 (depends on 1) The method of claim 1, wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence selected from SEQ ID NO: 120, SEQ ID NO: 203, SEQ ID NO: 2 to SEQ ID NO: 112, SEQ ID NO: 114 to SEQ ID NO: 119, SEQ ID NO: 121 to SEQ ID NO: 145, SEQ ID NO: 147 to SEQ ID NO: 202, SEQ ID NO: 204 to SEQ ID NO: 273, and SEQ ID NO: 275 to SEQ ID NO: 328. ### Claim 14 (depends on 1) The method of claim 1, wherein the immune response comprises a cytotoxic T cell response. ### Claim 15 (depends on 1) The method of claim 1, wherein the cancer is non-Hodgkin lymphomas. ### Claim 16 (depends on 1) The method of claim 1, wherein the cancer is acute myelogenous leukemia. ### Claim 17 A method of treating a HLA-A*02+ patient who has cancer, comprising administering to the patient a population of activated antigen-specific CD8+ cytotoxic T cells that kill cancer cells that present at their surface a peptide consisting of the amino acid sequence selected from SEQ ID NO: 120, SEQ ID NO: 203, SEQ ID NO: 2 to SEQ ID NO: 112, SEQ ID NO: 114 to SEQ ID NO: 119, SEQ ID NO: 121 to SEQ ID NO: 145, SEQ ID NO: 147 to SEQ ID NO: 202, SEQ ID NO: 204 to SEQ ID NO: 273, and SEQ ID NO: 275 to SEQ ID NO: 328 in a complex with an MHC class I molecule, wherein the activated antigen-specific CD8+ cytotoxic cells are produced by a method comprising contacting in vitro CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of the amino acid sequence selected from SEQ ID NO: 120, SEQ ID NO: 203, SEQ ID NO: 2 to SEQ ID NO: 112, SEQ ID NO: 114 to SEQ ID NO: 119, SEQ ID NO: 121 to SEQ ID NO: 145, SEQ ID NO: 147 to SEQ ID NO: 202, SEQ ID NO: 204 to SEQ ID NO: 273, and SEQ ID NO: 275 to SEQ ID NO: 328 in a complex with an MHC class I molecule, wherein said cancer is selected from the group consisting of non-Hodgkin lymphomas, acute myelogenous leukemia, chronic lymphocytic leukemia, uterine cancer, lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, and bile duct cancer. ### Claim 18 (depends on 17) The method of claim 17, wherein the T cells are autologous to the patient. ### Claim 19 (depends on 17) The method of claim 17, wherein the cancer is non-Hodgkin lymphomas. ### Claim 20 (depends on 17) The method of claim 17, wherein the cancer is acute myelogenous leukemia.